Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (301-310 of 379) with videos related to

Pageof 38
Sort By:
Blood|September 16, 2011
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphomaBoris Böll, Henning Bredenfeld, Helen Görgen, et al.
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social ReintegrationKarolin Behringer, Helen Goergen, Horst Müller, et al.
The Journal of Pathology|March 25, 2014
Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphomaHinrich P Hansen, Hanna-Mareike Engels, Maria Dams, et al.
American Journal of Hematology|August 10, 2019
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphomaSylvia Hartmann, Annette Plütschow, Anja Mottok, et al.
Blood|April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphomaAchim Rothe, Stephanie Sasse, Max S Topp, et al.
Cancer Treatment Reviews|April 3, 2007
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysisAlexander Greb, Julia Bohlius, Sven Trelle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trialsBoris Böll, Helen Görgen, Michael Fuchs, et al.
British Journal of Haematology|June 27, 2014
Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG)Sylvia Hartmann, Dennis A Eichenauer, Annette Plütschow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupStephanie Sasse, Helen Goergen, Annette Plütschow, et al.
Pageof 38

Showing results (301-310 of 379) with videos related to

Sort By:
Pageof 38
Blood|September 16, 2011
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphomaBoris Böll, Henning Bredenfeld, Helen Görgen, et al.
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social ReintegrationKarolin Behringer, Helen Goergen, Horst Müller, et al.
The Journal of Pathology|March 25, 2014
Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphomaHinrich P Hansen, Hanna-Mareike Engels, Maria Dams, et al.
American Journal of Hematology|August 10, 2019
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphomaSylvia Hartmann, Annette Plütschow, Anja Mottok, et al.
Blood|April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphomaAchim Rothe, Stephanie Sasse, Max S Topp, et al.
Cancer Treatment Reviews|April 3, 2007
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysisAlexander Greb, Julia Bohlius, Sven Trelle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trialsBoris Böll, Helen Görgen, Michael Fuchs, et al.
British Journal of Haematology|June 27, 2014
Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG)Sylvia Hartmann, Dennis A Eichenauer, Annette Plütschow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupStephanie Sasse, Helen Goergen, Annette Plütschow, et al.
Pageof 38